Evaluation and Management of Mastalgia
The evaluation of mastalgia should be stratified by pain characteristics (cyclical vs. focal/noncyclical) and patient age, with most women requiring only reassurance after excluding malignancy, while focal noncyclical pain warrants age-appropriate imaging per ACR guidelines. 1
Initial Clinical Assessment
Categorize the Pain Pattern
Cyclical mastalgia (diffuse, bilateral, premenstrual, >1 quadrant): This represents physiologic breast pain related to hormonal fluctuations and does not require imaging beyond routine screening recommendations 1
Noncyclical focal mastalgia (localized to one area, unilateral, persistent): This requires imaging evaluation to exclude malignancy, though cancer risk remains low (typically <2%) 1, 2
Extramammary pain: Evaluate for musculoskeletal causes (costochondritis, chest wall pain) which may masquerade as breast pain 2
Key History Elements
- Medication review: Oral contraceptives, hormone therapy, psychotropic drugs, and cardiovascular agents can cause mastalgia 3
- Associated symptoms: Exclude nipple discharge or palpable masses which require different diagnostic pathways 3
- Duration and severity: Pain lasting >5 days per month or interfering with daily activities warrants treatment beyond reassurance 4
Imaging Recommendations for Focal Noncyclical Pain
Age-Based Algorithm (ACR Appropriateness Criteria)
Women <30 years: Ultrasound is the appropriate initial imaging modality 1
Women 30-39 years: Either mammography (including digital breast tomosynthesis) OR ultrasound are appropriate equivalent alternatives 1
Women ≥40 years: Mammography/digital breast tomosynthesis is appropriate, complementary to ultrasound 1
Recent imaging: If mammography was performed within 3-6 months, proceed directly to ultrasound 1
Imaging Performance Characteristics
- Mammography demonstrates 100% sensitivity and negative predictive value for excluding malignancy in focal breast pain 1
- Ultrasound specificity is 95% for nondense breasts and 87% for dense breasts 1
- Most imaging abnormalities found are benign (small cysts, benign masses) that rarely require intervention 1
Management Strategy
First-Line Interventions (Effective in 70-92% of Cases)
Reassurance alone resolves symptoms in the majority of women once malignancy is excluded 5, 4
Proper bra fitting: A well-fitted, supportive bra provides mechanical support and reduces pain 6, 5
Topical NSAIDs: Apply to affected area; provides relief in 70-92% of women with persistent symptoms 5
Dietary modifications: Reduce coffee and dietary fat intake (modest benefit demonstrated) 5
Second-Line Medical Therapy (For Refractory Cases)
Only consider after first-line measures fail, as these medications carry significant side effects:
Ormeloxifene (Selective Estrogen Receptor Modulator): Most effective with fewest side effects, though not licensed in all countries 5
Dopamine agonists: Useful but less effective than endocrine treatments 5
Danazol or Tamoxifen: Effective but cause androgenic or menopausal side effects; reserve for severe refractory cases 5, 4
Adjunctive Therapies
- Oral NSAIDs or acetaminophen: For symptomatic relief 3
- Relaxation therapy, acupuncture: May provide benefit but lack robust evidence 5
Critical Management Pitfalls
Do NOT image cyclical, diffuse breast pain: This leads to unnecessary radiation exposure, false positives, and increased patient anxiety without improving outcomes 1
Avoid prescribing hormonal therapies as first-line: The side effect profile (androgenic effects, menopausal symptoms) outweighs benefits for most patients 5, 4
Do NOT assume ultrasound-detected small cysts require aspiration: Without a palpable abnormality, small cysts are unlikely to cause pain or benefit from intervention 1
Referral Indications
Refer to a breast care specialist when: